Precision Medicine Investors

Creating and investing in life sciences companies that target our world's most urgent medical needs.We chose the last letter of the Greek alphabet Ω as our brand because we start our investment process by focusing on the end goal - delivering impactful medicines to patients.Our investment process starts by focusing on how we can deliver impactful medicines to patients.We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others.Early seed or late stage public financing. Large markets or rare diseases.
Established targets or novel technologies.We are guided by our conviction in people, products and breakthrough ideas, not by conventional categories.We focus on great people and great science everywhere, with a special concentration on North America and Western Europe.Our investment decisions are honed by cross-disciplinary teams analyzing platforms and products across disease areas.We work in partnership with our companies’ founders, management teams and fellow co-investors to provide necessary resources: domain knowledge and perspective, network connectivity, and capital.Our investments span a variety of instruments from early venture rounds, to late-stage investing, direct secondary transactions, as well as company founding and creation.Omega Funds has invested in more than 150 innovative life sciences companies since its inception. Those investments have led to 46 marketed products, many changing the course of treatment for patients with devastating diseases such as acute lymphoblastic leukemia, melanoma, and Huntington’s disease.

Altaris, LLC is a private equity firm specializing in corporate carve outs and partnerships, acquisitions, debt financing, private equity / buyouts fund, venture capital fund, recapitalization, divestitures, strategic co-ownership arrangements, leverage buyouts, PIPES, middle market, industry consolidation and growth capital investments. It prefers to invest in pharmaceuticals, therapeutics, contract development and manufacturing, drug delivery technologies, medical devices, outsourced design and manufacturing, supply chain, minimally invasive technologies, life sciences and diagnostics, bioprocessing, advanced imaging & precision medicine, R&D efficiency, healthcare services, technology-enabled services, digitization of processes, and preventative care and wellness sectors. The firm prefers to invests in companies in the United States, Canada, North America and Western Europe. It prefers to invest in equity investment between $50 million and $500 million. It makes control, majority, and significant minority investments. Altaris, LLC was founded in 2003 and is based in New York, New York.

Quan Capital is a venture capital firm specializing in incubation, early stage, startups, and growth stage investments. The firm seeks to invest in the healthcare, life sciences, pharmaceutical, biotech, and biomedical sector with a specific focus on therapeutic biopharmaceutical, enabling technologies, companion diagnostic, precision medicine and artificial intelligence. The firm prefers to invest globally. Quan Capital was founded on 2016 and is based in Shanghai, China. with additional office in Palo Alto, California.

Delian Capital is a venture capital firm specializing in mid- and early- stage investments. The firm prefers to invest in the field of hard and core technology; advanced manufacturing (robots, smart manufacturing, semiconductors and photoelectric, communication and 5G); cutting-edge technology (artificial intelligence, IoT, intelligent equipment, cloud native, third-generation treatment technology, enterprise services, information security, smart vehicle); to B hardware and solutions; and medical healthcare (innovative medicine, innovative medical treatment, biotechnology, precision medicine, and digital medicine). For innovative medicine, it seeks to invest in mid- to early- stage investments in third-generation therapeutic technology (cell therapy, gene therapy, gene editing, small nucleic acid). For semiconductors, the firm prefers to invest in chip design, materials and equipment, advanced packaging, IDM laser, radio frequency microwave, storage and internet of things. The firm seeks to invest in China and overseas. It was founded in 2011 and is based in China.

Kayan Ventures is a venture capital firm specializing in start-ups & early-stage investments. The firm invests in deep tech, data-driven, AI-powered or potentially enabled, innovatively and positively disruptive companies that works on novel and essential technologies, health tech with focus on medical devices, life sciences & longevity, artificial intelligence & machine learning, health data analytics & digital therapeutics, preventative medicine & early diagnostics; climate tech with focus on battery technology & EV adoption, precision agriculture & sustainable farming, analytics & IoT, built environment & sustainable materials, food & water security; deep-tech; data-driven and scalable solutions. It seeks to invest globally. Kayan Ventures is based in United Arab Emirates.

Nextech Invest is a Zurich-based venture capital firm specializing in precision medicine and biotechnology, specifically focused on identifying and fueling transformative cancer medicines globally.

PsyMed Ventures is a venture capital firm dedicated to revolutionizing brain and mental health through innovative neuroscience and frontier technologies. The firm focuses on investing in frontier technologies transforming the mental and brain illness epidemic into a flourishing future. Their investment areas include Artificial Intelligence, Neurotech & Human Augmentation, Precision Psychiatry, Digital Therapeutics, Holistic Medicine, Metabolic Psychiatry, and Psychedelic Medicine & New Compounds. PsyMed Ventures supports founders who align healing, responsibility, and profitability.

Section 32, LLC is a venture capital firm specializing in series C, growth capital investments. It seeks to invest in technology which includes cybersecurity, therapeutics, advanced diagnostics, precision medicine, enterprise software, fintech, web3, quantum computing, space, machine learning, artificial intelligence, computational biology,Healthcare, advanced communications and computation, climate change related technologies, genomics, life sciences, software, agriculture technology and biotechnology. Section 32, LLC was founded in 2017 and is based in Silicon Valley, California with additional offices in San Diego, California, Boston, Massachusetts, Los Altos, California, San Francisco, California and Palo Alto, California.

Coronet Ventures is a venture capital specializing in seed to series A, early-stage and startup investments. The firm seeks to invest in healthcare, biomedical science, biotech, medtech, healthtech, cell and gene therapy, pharmaceutical, medical devices, clinical decision support tools, precision medicine, value based diagnostics, AI/machine learning, digital health and clinical trials. The firm prefers to invest in United States, Singapore and Netherland region. The firm seeks to invest in US$0.5 million and US$ 3 million. Coronet Ventures is based in Singapore, Singapore with an additional office in Amsterdam, Netherlands. Coronet Ventures is a venture capital arm of Cedars-Sinai Medical Center.

Illumina Ventures is an independently managed venture capital firm specializing in genomics and precision health investments. Established in 2016, the firm focuses on early-stage companies that are pioneering new applications of genomics and enabling precision medicine. Their strategic partnership with Illumina, Inc. (NASDAQ: ILMN) provides access to the expertise and vision of the world's leading genomics solutions provider. This collaboration enables Illumina Ventures to identify and build companies that will transform healthcare and the world. The firm's investment areas include life science tools, diagnostics, therapeutics, digital health, and sustainability. Through Illumina Ventures Labs, they offer capital, sequencing, mentorship, and fully equipped genomics lab capabilities to accelerate value creation for early-stage genomics startups.

PM Equity Partner is a private equity and venture capital arm of Philip Morris International Inc. specializing in investing in early-stage companies. The firm prefers to invest in Southeast Asia. The firm usually invests in healthier FMCG, human health, environmental health. Within healthier FMCG, it focuses on solutions for healthier food, and beverage, and reduced-risk tobacco products. Within human health, it focuses on healthcare solutions including omics and digital health, diagnostics and tailored medicine, with a special interest in pulmonary delivery platforms. Within environmental health, it focuses on sustainable environment, precision farming, performance crops and smart fertilizers, as well as innovative recycling techniques, bio-remediation, cleanTech, agroTech and wastewater treatment. The firm prefers to take ticket size between $2 million to $ 50 million. It invests globally. It takes minority investments usually between 10% to 30%. PM Equity Partner was formed in 2015 and is based in Lausanne, Switzerland.

Scientia Ventures, previously known as New Ventures Fund, is a venture capital firm specializing in investments in early to mid stage companies and growth capital. The firm prefers to invest in healthcare sector, with a focus on therapeutics, pharmaceuticals, drug development companies, precision medicine and diagnostics. It seeks to invest globally. Scientia Ventures is based in New York, New York.

We invest in promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is focused on building world-class Canadian companies (and companies associated with Canadian talent and IP) in precision medicine and next-generation medical devices.

Gore Range Capital is a specialized healthcare investment firm focused on building science-led platforms across precision health, regenerative medicine, personalized therapeutics, longevity, and restorative medical sciences. The Firm invests in innovative companies developing next-generation healthcare solutions designed to improve functional health, enhance quality of life, and support long-term wellbeing.

Middleland Capital is a venture capital firm specializing in seed/startup, early-stage and growth capital investments. The firm seeks to invest in agriculture companies, global technologies, and emerging markets. The firm invests holistically across the entire food value-chain with focus on foodtech and agtech companies, crop technology, digital agriculture, food & health innovation, supply chain technology, food innovation; engineering services, life science tools and services, upstream includes crop inputs and protection, precision agriculture, controlled environment agriculture, plant science; midstream includes marketplaces and fintech, animal health, sensors and farm IoT; downstream includes novel food and ingredients, food waste and sustainable packaging, efood, food as medicine. The firm seeks to improve resource efficiency, contribute to better farm life, create smarter supply chains and advance food nutrition. The firm prefer to invest globally with a focus on Virginia. The firm seeks to invest up to $5 million in companies. Middleland Capital is based in Washington, District of Columbia with an additional office in London, United Kingdom.

WinDigital Capital is a venture capital firm specializing in early stage accelerated incubation. The firm prefers to invest in artificial intelligence, big data, deep learning, technology manufacturing, collaborative robots, financial technology, big health, life sciences, biomedicine, precision medicine, and new consumer sectors. It typically makes follow-on investments. The firm seeks to build a combination of “venture capital + intellectual property + R&D outsourcing services” incubation ecology. It was founded in 2016 and is based in Beijing, China.

Founder H Fund Co., Ltd. is a venture capital firm specializing in Pre-IPO, startup, early, growth capital, mid-venture and mature stage investments. It invests in medical information technology, precision medicine, financial service, technology, media, and telecommunication, medical field, cultural education, children education, artificial intelligence, information technology, intelligent manufacturing, commercial aerospace, new materials, new energy, real estate, new third board and bulk commodity sectors. For technology, the firm seeks to invest in growth capital in strategic emerging areas with a focus on aerospace equipment, unmanned systems, new generation information technology, biomedicine and high-performance medical equipment, high-performance materials, and artificial intelligence. For technology, it also prefers to invest in early stage in high-end hard and core technology original innovation stage projects. For the medical field, the firm seeks to invest in growth capital in health-related sectors such as medical services, pharmaceutical, medical equipment medical information technology. For the medical field, it also prefers to invest in early to mid-stage in new technology including precision medicine, medical devices, drug research and development, medical services. It seeks to invest in industries that are being supported or encouraged by the People's Republic of China. The firm seeks to invest in China. It invests mainly through M&A. The firm seeks to have a controlling stake or minority stake in equity. It will exit its portfolio companies through IPO, M&A, or trade. It seeks cross-border investments. Founder H Fund Co., Ltd. was founded in 2010 and is based in Beijing, China with an additional office in Shanghai, China and Wuhan, China. It operates as a investment arm of Founder Securities Co., Ltd.

A clinician-driven venture capital firm based in Silicon Valley investing in early-stage healthcare and precision medicine startups, supported by a network of over 2,000 medical experts.

Founded over 20 years ago, Kaiser Permanente Ventures has developed into a national leader in strategic venture investing in healthcare. In partnership with Kaiser Permanente and our limited partners, the KPV team has invested in and helped support over 65 companies, representing some of the most important innovations in healthcare delivery over this time period. We’ve achieved these successes through deep engagement within KP and across our investment partners, leveraging the tremendous insights that come from those leading our healthcare systems and care delivery to identify the most pressing needs within healthcare and select the innovations that most effectively address those opportunities.Together with our partners, KP and KPV represents22,000+ clinicians and over 180,000 healthcare employees38+ acute care hospitals and over 600 other healthcare related facilitiesApproximately $65 billion in annual operating revenueLargest U.S. single comprehensive electronic medical record systemLeading evidence-based care delivery modeOur fund targetsHealth Information Technology (Enterprise Solutions)Digital HealthHealthcare ServicesMedical DevicesDiagnostics and Precision MedicineKP Ventures (KPV) is one of the longest tenured and strongest strategic venture investment programs in the healthcare industry. Over 20 years and through 65+ investments to date, the KPV team has effectively leveraged the tremendous insights resident in Kaiser Permanente and its investment partners to identify and successfully invest in innovative companies addressing some of the most pressing and important challenges facing the healthcare system.

Red Horse Investments Group is a venture capital and private equity investment firm specializing in pre-IPO, M&A, management buyout, refinancing and restructuring investment. For M&A, the firm prefers to invest in mining, energy, electricity, steel, transportation, new materials, energy conservation and environmental protection and participates in restructuring and M&A of large central enterprises, state-owned enterprises, and national or regional companies. It seeks to invest in high technology focusing on artificial intelligence, semiconductors, big data, cloud, new materials, innovative and digital medical treatment; natural resources focusing on coal, oil, natural gas, ferrous metals, non-ferrous metals, and precious metals, high-quality non-metallic mineral resources, and resource-related industry projects; environmental protection and energy saving, with an attentive focus on high-growth companies in the domain of new materials, energy saving technology and equipment, new technologies, technology services and new energy concepts; biotechnology with a focus on gene biology, innovative medicine, precision medicine, medical equipment, health care; media: selected large publishing groups, film digitization, new media directed towards high growth projects; technology, media, telecommunications sector focusing on semiconductor chips, telecommunications, big data, cloud computing, information technology services, digitization, new media, games, digital videos; and Internet sector focusing on communications, fast-moving consumer goods and services, paying attention to emerging high growth developments and potential superior business models and technology projects. It also seeks to invest in asset management consulting business. The firm prefers to invest in China. It typically exists through listing, reverse takeover, merger, management buyout or equity transfer of the portfolios. The firm was previously known as Asia Assets Limited. Red Horse Investment Group is based in Beijing, China.

Brightlands Venture Partners is a venture capital firm specializing in startup, early, growth, mid venture, and late venture companies. The firm invests in energy, life sciences advanced chemicals, resources, materials, and performance materials including polymers and drug delivery sectors with a focus on sustainable chemicals and smart materials, cleantech, regenerative medicine and biomedical materials, analytics, biomarkers, and diagnostics; also focuses on technology startups of agrifood and on innovations in crop protection and optimization, agriculture (seed and grow) and food (harvest and formulate), seed improvement, precision agriculture, valorization and horticultural waste and healthy nutrition . Within life sciences, it invests in regenerative medicine, drug delivery, drug screening and formulation and diagnostics, cardiovascular and oncology research, nutrition and health, biomaterials and biomedical devices, and biopharmaceuticals. In advanced materials, the fund focuses on functional polymers, coatings and films, formulations, applications and processing activities. The firm invests in Europe and North America. It invests in province of Limburg preferably to the Research Campus at Chemelot in north of Maastricht and Meuse-Rhine Euregion and it may also invest in companies in the wider region of the Leuven, Aachen, and Eindhoven triangle. The firm typically invests between €250,000 ($320,000) and €2 million ($2.55 million) per company initially and the maximum commitment per company is €4 million ($4.80 million). It can also provide follow on investments. It prefers to invest if a company benefits – and contributes to the Brightlands ecosystem. The firm makes investments in the form of equity and can also invest in the form of convertible loans. It also prefers to invest in a syndicate, takes the lead investor role, and helps find co-investors. It prefers to be a shareholder and takes a board seat in its portfolio companies. It can either be a lead investor or participate as co-investor in a consortium. It prefers to exit within 7 years. Brightlands Venture Partners was founded in 2014 and is based in Geleen, Netherlands.

Ecphora Capital Management Company, LLC is a venture capital firm specializing in early, startups and growth capital investments. The firm invests in med tech, healthcare, medicine, medical commercialization, biomedical tech startups, tech-enabled medical devices; biotech including novel therapies, precision medicine, gene editing, and regenerative medicine; digital health including leveraging data analytics, AI, telemedicine, and remote patient monitoring; and health tech sectors. The firm invests in Maryland. Ecphora Capital Management Company, LLC is based in Baltimore, Maryland.

Merck Global Health Innovation Fund, LLC is an accelerator and a venture capital arm of Merck & Co. Inc. specializing in direct and fund of fund investments. In direct investments, the firm specializes in seed/startup, early venture and growth equity investments. The firm invests in digital health and data science companies that facilitate and optimize biopharmaceutical operations with the goal of improving patient care. The firm seeks to invest in therapeutic devices; drug discovery and clinical development; manufacturing, supply chain and IT; access to medicine; digital health, healthcare, health care services, vaccines, consumer electronics, home furnishings, homebuilding, household appliances, housewares and specialties, leisure products, textiles, apparel and luxury goods, animal care products sectors. It seeks to invest in companies built around data, but which also touch on security, privacy, analytics and in areas such as diagnostics, precision medicine, clinical decision-support tools and patient engagement. The firm is geography agnostic with a focus on North America and Europe. In early-stage companies, it invests up to $2 million with up to 20% ownership. In areas aligned with business needs, it invests up to $10 million in series B and C companies with up to 20% ownership. When a business is signing multiyear multimillion services contract, it invests growth capital of minimum $10 million with up to 30% ownership. Overall, it invests up to $15 million in companies. Merck Global Health Innovation Fund, LLC was founded in 2010 and is based in Readington Township, New Jersey.

ShenZhen Co-Stone Asset Management Co., Ltd. is a venture capital firm specializing in angel, startups, early stage, growth stage, late stage, pre-IPO investments, mergers, acquisitions, and PIPE investments. The firm seeks to make investments in the fields of carbon neutrality, advanced manufacturing; semiconductors and integrated circuits; hard and core technology and new and emerging industries; big data and artificial intelligence; publishing and media; life sciences, medicine and medical treatment; healthcare; new energy; environmental protection culture; technology, media, telecommunications; tourism; consumer products and services; consumer upgrade; modern agriculture; and industrial 4.0. In advance manufacturing, it seeks to make investments in construction machinery, automobiles, automobile parts, precision manufacturing, machinery and power generating equipment, and foundry goods processing. In publishing and media, it seeks to make investments in print media, book publishing, distribution services, new media, film and television, web television, animation, cultural media services, integration of cultural entertainment and technology, and internet pan-entertainment. In medicine and medical treatment, it seeks to make investments in technology, medical equipment, Chinese medicines, chemical drugs, diagnostics, medicine logistics, internet medical care, medical services, and biotechnology. In new energy, it seeks to make investments in photovoltaic industry, fan and fan accessories manufacturing, lithium battery, new energy vehicles, and nuclear power. In TMT, it seeks to make investments in e-commerce, new media, mobile internet, online games, consumer electronics, software services, equipment suppliers, and outsourcing. In services, it seeks to make investments in logistics, financial, and modern services. In consumer products, it seeks to make investments in branded consumer products and retail services. In modern agriculture, it seeks to make investments in cultivation, modern farming, and agricultural feeds. It typically invests in companies based in China. In industrial 4.0, it seeks to make investments in robots, smart manufacturing, smart production, and smart factory. The firm typically invests in specialized, refined, special, and innovative enterprises. It seeks to make investments not greater than 20% of the fund and seeks to acquire 5% to 30% minority share for every portfolio company. The firm primarily exits its investments within one to three years through IPO, M&A, or backdoor. It practices ESG investing. Shenzhen Cornerstone of Entrepreneurial Cci Capital Ltd. was founded in 2001 and is based in Shenzhen, China with additional offices in Beijing, China, Hefei, China, Shanghai, China, Nanjing, China and Hong Kong.

China SDIC Gaoxin Industrial Investment Corp. Ltd. is a venture capital arm of State Development & Investment Corp., Ltd. specializing in the investment, acquisition and merger of early stage and fast-growth stage enterprise. The firm typically invests in small to medium size companies. It prefers to invest in modern information technology, 5G, advanced ceramics, biomanufacturing, semiconductor, high-temperature alloys, consumer electronics, high-tech industrial investment such as new materials, high-consumables, medical, software system integration, precision mechanism component, bioengineering, environment protection, information technology, life sciences, medical field, biology, telecommunications technology, new pharmaceutical, resource utilization, new model, rail transit high-end equipment, advanced manufacturing, aerospace, medicine, medical equipment, and new energy. The firm also invests in traditional areas, including international trade, logistics, investment consultation, information network and other relevant trade and service. It prefers to invest in Zhangjiagang City and in Guangdong Province, especially in Guangzhou City, China. China SDIC Gaoxin Industrial Investment Corp. Ltd. was founded in 1988 and is based in Beijing, China.